Quantcast

Latest Telik Inc. Stories

2014-08-11 08:29:39

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, which recently merged with MabVax Therapeutics, Inc. on July 8, 2014, announced the appointment of six new members of the board of directors to help guide the company and its management in developing an expanded product development pipeline post-merger. "We are pleased to be able to attract such an outstanding new slate of board members who have both strong...

2014-08-04 08:29:16

SAN DIEGO, Aug. 4, 2014 /PRNewswire/ -- As previously announced, MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. (OTCQB: TELK), aclinical stage oncology drug development company, completed a merger transaction pursuant to which MabVax became a wholly owned subsidiary of Telik effective as of July 8, 2014, following Telik stockholder approval at Telik's annual meeting of stockholders, held on July 7, 2014. Following the merger, MabVax...

2014-05-15 16:28:36

PALO ALTO, Calif., May 15, 2014 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2014. The net loss for the quarter ended March 31, 2014 was $1.1 million, or $0.23 per share, compared with a net loss of $1.9 million, or $0.46 per share, for the same period in 2013. Total research and development expenses (R&D) in the first quarter of 2014 were $0.3 million, compared to $0.8 million for the same period in 2013....

2014-05-12 16:29:32

PALO ALTO, Calif., May 12, 2014 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK), a clinical stage oncology drug development company, and MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, have entered into a definitive merger agreement. Upon closing of the transaction, MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. Under the terms of the merger...

2014-05-12 16:29:28

SAN DIEGO, May 12, 2014 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held cancer immunotherapy company and Telik, Inc. (Nasdaq: TELK), aclinical stage oncology drug development company have entered into a definitive merger agreement. Upon closing of the transaction, MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. Under the terms of the merger agreement,...

2014-03-10 16:33:03

PALO ALTO, Calif., March 10, 2014 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $0.8 million, or $0.17 per share, for the three months ended December 31, 2013, compared with a net loss of $1.8 million, or $0.66 per share, for the comparable period in 2012. For the year ended December 31, 2013, net loss was $5.2 million, or $1.17 per share, compared with a net loss of $8.0 million, or $3.64 per share, for the year ended December 31, 2012. For the quarter ended December...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.